Namita Thapar, Emcure Pharmaceuticals Executive Director, is all set to earn approximately Rs 127.87 crore from the company's Initial Public Offering (IPO).
The Shark Tank India investor will sell about 12.68 lakh shares of her company through the Offer for Sale component.
It is anticipated that Thapar will receive an astounding 293-fold return on her initial investment.
After the company's IPO, Thapar is anticipated to collect about Rs 127 crore from the sale.
She first invested for an average of Rs 3.44 per share; that price has since climbed to Rs 960 to Rs 1,008 a share.
The price band ranges from Rs 960 to Rs 1,008 per equity share, each with a face value of Rs 10. With Rs 1,008 as the highest price band for the Emcure Pharmaceuticals IPO, Ms Thapar is expected to receive about Rs 127 crore from the sale.
Emcure Pharma IPO with a price band of Rs 960-1,008 per share, will close for public subscription on July 5.
Emcure Pharma’s IPO comprises fresh issuance of equity shares worth Rs 800 crore and an offer of sale (OFS) of 1.14 crore equity shares to the tune of Rs 1,152 crore, at the upper end of the price band, by promoters and existing shareholders.